GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (NAS:SCPH) » Definitions » Effective Interest Rate on Debt %

scPharmaceuticals (scPharmaceuticals) Effective Interest Rate on Debt % : 20.73% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is scPharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. scPharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $8.40 Mil. scPharmaceuticals's average total debt for the quarter that ended in Mar. 2024 was $40.54 Mil. Therefore, scPharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 20.73%.


scPharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for scPharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

scPharmaceuticals Effective Interest Rate on Debt % Chart

scPharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only 11.18 12.78 13.61 12.01 20.93

scPharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.91 21.25 21.18 20.90 20.73

Competitive Comparison of scPharmaceuticals's Effective Interest Rate on Debt %

For the Biotechnology subindustry, scPharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


scPharmaceuticals's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, scPharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where scPharmaceuticals's Effective Interest Rate on Debt % falls into.



scPharmaceuticals Effective Interest Rate on Debt % Calculation

scPharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -8.123/( (37.368+40.269)/ 2 )
=-1  *  -8.123/38.8185
=20.93 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=36.801 + 0.567
=37.368

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=40.093 + 0.176
=40.269

scPharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Mar. 2024 ))/ count )
=-1  *  -8.404/( (40.269+40.802)/ 2 )
=-1  *  -8.404/40.5355
=20.73 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=40.093 + 0.176
=40.269

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=40.618 + 0.184
=40.802

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


scPharmaceuticals  (NAS:SCPH) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


scPharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of scPharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


scPharmaceuticals (scPharmaceuticals) Business Description

Industry
Traded in Other Exchanges
Address
2400 District Avenue, Suite 310, Burlington, MA, USA, 01803
scPharmaceuticals Inc is a pharmaceutical company. Its pipeline includes products in various stages of clinical and non-clinical development. It focuses on pharmaceutical products in the cardiovascular and infectious disease therapeutic areas. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
Executives
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
5am Partners Iv, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jack A. Khattar director C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
John H Tucker director, officer: President and CEO INDEVUS PHARMACEUTICALS, INC., 99 HAYDEN AVENUE, LEXINGTON MA 02421
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
William Tober Abraham director C/O SCPHARMACEUTICALS INC., 2400 DISTRICT AVENUE, SUITE 310, BURLINGTON MA 01803
Sara Bonstein director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Andrew J. Schwab 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc other: See Remarks 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p. other: See Remarks 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
Orbimed Genesis Gp Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rachael Nokes officer: See Remarks C/O SCPHARMACEUITCALS, INC., 2400 DISTRICT AVENUE, BURLINGTON MA 01803